AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 31048638 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined AGV implantation and trabeculectomy revision with adjunctive antimetabolite
Number of subjects: 20
Study 27908840 — intervention group
Group type: EXPERIMENTAL
Intervention: Taper support intervention (psychiatric consultation, opioid dose tapering, and 18 weekly meetings with a physician assistant)
Number of subjects: 35
Study 27908840 — intervention group
Group type: EXPERIMENTAL
Intervention: Taper support intervention
Number of subjects: 35
Study 27908840 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 35
Study 26065500 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% natamycin (Group A)
Number of subjects: 115
Study 26065500 — intervention group
Group type: EXPERIMENTAL
Intervention: 200mg oral ketoconazole twice a day plus 5% natamycin (Group B)
Number of subjects: 115
Study 26065500 — intervention group
Group type: COMPARATOR
Intervention: Comparison between Group A and Group B
Number of subjects: 115
Study 23150531 — intervention group
Group type: EXPERIMENTAL
Intervention: Journey DPP
Number of subjects: 64
Study 23150531 — intervention group
Group type: COMPARATOR
Intervention: Health-oriented comparison condition
Number of subjects: 64
Study 19594906 — intervention group
Group type: EXPERIMENTAL
Intervention: e‐SBI with limited feedback
Number of subjects: 2858
Study 19594906 — intervention group
Group type: COMPARATOR
Intervention: e‐SBI with full feedback
Number of subjects: 2858
Study 16983674 — intervention group
Group type: EXPERIMENTAL
Intervention: Double-pass, low-energy treatment (8-11 J/cm²)
Number of subjects: 6
Study 16983674 — intervention group
Group type: COMPARATOR
Intervention: Single-pass, high-energy treatment (13-14 J/cm²)
Number of subjects: 6
Study 14972421 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetylcysteine (600mg orally t.i.d.)
Number of subjects: 80
Study 14972421 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 14972421 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetylcysteine
Number of subjects: 80
Study 11519636 — intervention group
Group type: EXPERIMENTAL
Intervention: Cocaine (200 mg)
Number of subjects: 6
Study 11519636 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate (15-90 mg)
Number of subjects: 6
Study 11519636 — intervention group
Group type: COMPARATOR
Intervention: Triazolam (0.125-0.75 mg)
Number of subjects: 6
Study 11519636 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 9762776 — intervention group
Group type: EXPERIMENTAL
Intervention: Specific IgA antibodies to Dermatophagoides farinae
Number of subjects: 28
Study 9762776 — intervention group
Group type: EXPERIMENTAL
Intervention: Specific IgA antibodies to Streptococcus pneumoniae
Number of subjects: 28
Study 9762776 — intervention group
Group type: EXPERIMENTAL
Intervention: Specific IgG antibodies to Dermatophagoides farinae
Number of subjects: 28
Study 9762776 — intervention group
Group type: COMPARATOR
Intervention: Specific IgG antibodies to Streptococcus pneumoniae
Number of subjects: 28
Study 9762776 — intervention group
Group type: EXPERIMENTAL
Intervention: Eosinophil cationic protein (ECP) levels
Number of subjects: 28
Study 8158764 — intervention group
Group type: EXPERIMENTAL
Intervention: Papaverine
Number of subjects: 0
Study 8158764 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostaglandin E1
Number of subjects: 0
Study 8158764 — intervention group
Group type: EXPERIMENTAL
Intervention: 15‐keto‐13,14‐dihydro‐prostaglandin E1 (metabolite of Prostaglandin E1)
Number of subjects: 0
Study 3354494 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 g of fructose
Number of subjects: 0
Study 3354494 — intervention group
Group type: COMPARATOR
Intervention: 50 g of glucose
Number of subjects: 0
Study 3354494 — intervention group
Group type: EXPERIMENTAL
Intervention: Fructose or glucose in a mixed meal format
Number of subjects: 0
Study 31650181 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher serum calcium levels (measured as standard deviation increase)
Number of subjects: 11034
Study 31650181 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetic predisposition to higher serum calcium levels
Number of subjects: 11034
Study 30056030 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 mg risankizumab every 4 weeks for 12 weeks (open-label intravenous therapy)
Number of subjects: 108
Study 30056030 — intervention group
Group type: EXPERIMENTAL
Intervention: Open-label subcutaneous risankizumab (180 mg) every 8 weeks for 26 weeks (maintenance phase)
Number of subjects: 108
Study 30056030 — intervention group
Group type: EXPERIMENTAL
Intervention: Open-label intravenous risankizumab (600 mg)
Number of subjects: 108
Study 30056030 — intervention group
Group type: EXPERIMENTAL
Intervention: Open-label subcutaneous risankizumab (180 mg)
Number of subjects: 108
Study 28116804 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin 300 mg
Number of subjects: 8
Study 28116804 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 26447746 — intervention group
Group type: COMPARATOR
Intervention: Blocked practice schedule (low contextual interference)
Number of subjects: 40
Study 26447746 — intervention group
Group type: EXPERIMENTAL
Intervention: Random practice schedule (high contextual interference)
Number of subjects: 40
Study 24126646 — intervention group
Group type: EXPERIMENTAL
Intervention: MARS with conventional treatment (n = 53)
Number of subjects: 102
Study 24126646 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment (n = 49)
Number of subjects: 102
Study 21553346 — intervention group
Group type: EXPERIMENTAL
Intervention: Project Support intervention
Number of subjects: 66
Study 21553346 — intervention group
Group type: COMPARATOR
Intervention: Existing services comparison condition
Number of subjects: 66
Study 18451376 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoride treatment (1.23 percent sodium fluoride)
Number of subjects: 30
Study 18451376 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 17198066 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium phosphate (NaP) tablets
Number of subjects: 845
Study 17198066 — intervention group
Group type: COMPARATOR
Intervention: 4-L polyethylene glycol (PEG) solution
Number of subjects: 845
Study 12975595 — intervention group
Group type: EXPERIMENTAL
Intervention: Quinapril (titrated to 40 mg/day) for 6 months
Number of subjects: 74
Study 12975595 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 6 months
Number of subjects: 74
Study 12975595 — intervention group
Group type: EXPERIMENTAL
Intervention: Quinapril
Number of subjects: 74
Study 12975595 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 74
Study 10752751 — intervention group
Group type: EXPERIMENTAL
Intervention: 5N15 glutamine in children with severe burns
Number of subjects: 5
Study 10752751 — intervention group
Group type: COMPARATOR
Intervention: Elective scar reconstruction (control group)
Number of subjects: 5
Study 8884414 — intervention group
Group type: EXPERIMENTAL
Intervention: Isometric exercise (neutral ankle angle)
Number of subjects: 12
Study 8884414 — intervention group
Group type: EXPERIMENTAL
Intervention: Eccentric exercise
Number of subjects: 12
Study 8884414 — intervention group
Group type: EXPERIMENTAL
Intervention: Concentric exercise
Number of subjects: 12
Study 8884414 — intervention group
Group type: COMPARATOR
Intervention: No exercise
Number of subjects: 12
Study 8884414 — intervention group
Group type: EXPERIMENTAL
Intervention: All exercise conditions
Number of subjects: 12
Study 1587378 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.625 mg/day conjugated estrogens cyclically (CE; 25 days/month)
Number of subjects: 84
Study 1587378 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.625 mg/day conjugated estrogens continuously
Number of subjects: 84
Study 1587378 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 micrograms/day of transdermal 17 beta‐estradiol cyclically (24 days/month)
Number of subjects: 84
Study 1587378 — intervention group
Group type: COMPARATOR
Intervention: Treatment-free control group
Number of subjects: 84
Study 3983885 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulised salbutamol 1.25 mg
Number of subjects: 32
Study 3983885 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulised salbutamol 2.5 mg
Number of subjects: 32
Study 3983885 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulised salbutamol 5 mg
Number of subjects: 32
Study 3983885 — intervention group
Group type: COMPARATOR
Intervention: Control (oxygen and corticosteroid treatment withheld)
Number of subjects: 32
Study 30417851 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketofol 1:1 mixture
Number of subjects: 90
Study 30417851 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketofol 1:2 mixture
Number of subjects: 90
Study 30417851 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketofol 1:4 mixture
Number of subjects: 90
Study 26638048 — intervention group
Group type: EXPERIMENTAL
Intervention: External focus
Number of subjects: 42
Study 26638048 — intervention group
Group type: EXPERIMENTAL
Intervention: Internal focus
Number of subjects: 42
Study 26638048 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 42
Study 24851869 — intervention group
Group type: EXPERIMENTAL
Intervention: Pneumoconiosis patients
Number of subjects: 19
Study 23080237 — intervention group
Group type: EXPERIMENTAL
Intervention: Silver alginate powder dressing
Number of subjects: 34
Study 23080237 — intervention group
Group type: COMPARATOR
Intervention: Foam dressing (control)
Number of subjects: 34
Study 23080237 — intervention group
Group type: COMPARATOR
Intervention: Comparison of silver alginate powder vs foam dressing
Number of subjects: 34
Study 20302428 — intervention group
Group type: EXPERIMENTAL
Intervention: Case patients with VAP
Number of subjects: 30
Study 20302428 — intervention group
Group type: COMPARATOR
Intervention: Control patients without VAP
Number of subjects: 30
Study 18593851 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxytocin
Number of subjects: 10
Study 18593851 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 18593851 — intervention group
Group type: EXPERIMENTAL
Intervention: LPS
Number of subjects: 10
Study 18593851 — intervention group
Group type: EXPERIMENTAL
Intervention: LPS + Oxytocin
Number of subjects: 10
Study 16033247 — intervention group
Group type: EXPERIMENTAL
Intervention: 3% cork extract gel
Number of subjects: 15
Study 16033247 — intervention group
Group type: COMPARATOR
Intervention: placebo gel
Number of subjects: 15
Study 12445027 — intervention group
Group type: COMPARATOR
Intervention: Co-artemether (artemether-lumefantrine) alone
Number of subjects: 16
Study 12445027 — intervention group
Group type: EXPERIMENTAL
Intervention: Co-artemether with ketoconazole (400 mg on day 1 followed by 200 mg o.d. for 4 additional days)
Number of subjects: 16
Study 12445027 — intervention group
Group type: EXPERIMENTAL
Intervention: Co-artemether with ketoconazole
Number of subjects: 16
Study 10337542 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol
Number of subjects: 48
Study 10337542 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 8938003 — intervention group
Group type: EXPERIMENTAL
Intervention: Long row of evenly spaced dots presented in counterphase with a blank interval of 15 ms between frames
Number of subjects: 0
Study 8938003 — intervention group
Group type: EXPERIMENTAL
Intervention: Long row of evenly spaced dots presented in counterphase with luminance polarity reversed on successive frames
Number of subjects: 0
Study 8938003 — intervention group
Group type: EXPERIMENTAL
Intervention: Single dot displaced over small distances under the same conditions
Number of subjects: 0
Study 8938003 — intervention group
Group type: EXPERIMENTAL
Intervention: Long row of displaced dots with weakened activation of motion detectors
Number of subjects: 0
Study 1743751 — intervention group
Group type: EXPERIMENTAL
Intervention: Lincomycin 300 mg intramuscularly daily in a single dose
Number of subjects: 150
Study 6852325 — intervention group
Group type: EXPERIMENTAL
Intervention: Amcinonide preparations and Betnovate cream applied once daily
Number of subjects: 10
Study 6852325 — intervention group
Group type: EXPERIMENTAL
Intervention: Amcinonide preparations and Betnovate cream applied twice daily
Number of subjects: 10
Study 6852325 — intervention group
Group type: EXPERIMENTAL
Intervention: Amcinonide preparations and Betnovate cream applied every alternate day
Number of subjects: 10
Study 6852325 — intervention group
Group type: EXPERIMENTAL
Intervention: Amcinonide preparations and Betnovate cream with an initial three times daily loading dose on the first day
Number of subjects: 10
Study 31315515 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral contralaterally controlled functional electrical stimulation (CCFES)
Number of subjects: 15
Study 31315515 — intervention group
Group type: COMPARATOR
Intervention: Unilateral cyclic neuromuscular electrical stimulation (cNMES)
Number of subjects: 15
Study 30138015 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone plus brief counseling
Number of subjects: 128
Study 26885762 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrate-rich (NR) supplementation
Number of subjects: 14
Study 26885762 — intervention group
Group type: COMPARATOR
Intervention: Nitrate-poor (NP) supplementation
Number of subjects: 14
Study 25316112 — intervention group
Group type: EXPERIMENTAL
Intervention: Warmed fluids
Number of subjects: 226
Study 25316112 — intervention group
Group type: EXPERIMENTAL
Intervention: Warmed underbody pad
Number of subjects: 226
Study 25316112 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 226
Study 22512509 — intervention group
Group type: EXPERIMENTAL
Intervention: 12 NB‐UVB exposures over 4 weeks (mean cumulative dose 48·4 standard erythema doses)
Number of subjects: 63
Study 22512509 — intervention group
Group type: COMPARATOR
Intervention: 20 μg of oral cholecalciferol daily for 4 weeks
Number of subjects: 63
Study 19914567 — intervention group
Group type: EXPERIMENTAL
Intervention: Various interventions from reviewed RCTs
Number of subjects: 78
Study 19914567 — intervention group
Group type: COMPARATOR
Intervention: Control group interventions from reviewed RCTs
Number of subjects: 78
Study 17972377 — intervention group
Group type: EXPERIMENTAL
Intervention: Implantable Cardioverter-Defibrillator (ICD) therapy
Number of subjects: 0
Study 17972377 — intervention group
Group type: EXPERIMENTAL
Intervention: ICD therapy for primary prevention
Number of subjects: 0
Study 17972377 — intervention group
Group type: EXPERIMENTAL
Intervention: ICD therapy for secondary prevention
Number of subjects: 0
Study 17972377 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy
Number of subjects: 0
Study 15814547 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacrolimus (0.2 mg/kg/day p.o.)
Number of subjects: 205
Study 15814547 — intervention group
Group type: COMPARATOR
Intervention: Cyclosporin-ME (7 mg/kg/day p.o.)
Number of subjects: 205
Study 15814547 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Number of subjects: 205
Study 15814547 — intervention group
Group type: COMPARATOR
Intervention: Cyclosporin-ME
Number of subjects: 205
Study 11823896 — intervention group
Group type: EXPERIMENTAL
Intervention: Chromium treatment (400 microg daily)
Number of subjects: 0
Study 11823896 — intervention group
Group type: COMPARATOR
Intervention: Chromium treatment
Number of subjects: 0
Study 12666956 — intervention group
Group type: EXPERIMENTAL
Intervention: AmF/SnF2 toothpaste (Meridol)
Number of subjects: 103
Study 12666956 — intervention group
Group type: COMPARATOR
Intervention: NaF toothpaste (control)
Number of subjects: 103
Study 7801960 — intervention group
Group type: EXPERIMENTAL
Intervention: Case histories identifying the patient's race as black
Number of subjects: 197
Study 7801960 — intervention group
Group type: COMPARATOR
Intervention: Case histories identifying the patient's race as white
Number of subjects: 197
Study 2150170 — intervention group
Group type: EXPERIMENTAL
Intervention: Chelon glass ionomer cement
Number of subjects: 0
Study 2150170 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketac-Fil glass ionomer cement
Number of subjects: 0
Study 2150170 — intervention group
Group type: COMPARATOR
Intervention: Conventional composite resin
Number of subjects: 0
Study 361057 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenoprofen 200 mg and Paracetamol 500 mg (combination)
Number of subjects: 0
Study 361057 — intervention group
Group type: COMPARATOR
Intervention: Fenoprofen 200 mg (separate)
Number of subjects: 0
Study 361057 — intervention group
Group type: COMPARATOR
Intervention: Paracetamol 500 mg (separate)
Number of subjects: 0
Study 361057 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 31931678 — intervention group
Group type: EXPERIMENTAL
Intervention: Wealth simple-categorization dominant (observer perspective)
Number of subjects: 0
Study 31931678 — intervention group
Group type: EXPERIMENTAL
Intervention: Age simple-categorization dominant (actor perspective)
Number of subjects: 0
Study 31931678 — intervention group
Group type: EXPERIMENTAL
Intervention: Wealth simple-categorization dominant (actor perspective)
Number of subjects: 0
Study 31931678 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 31931678 — intervention group
Group type: EXPERIMENTAL
Intervention: Simple-categorization dominance (Study 2)
Number of subjects: 0
Study 30701554 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 g of green cardamom for 10 weeks
Number of subjects: 83
Study 30701554 — intervention group
Group type: COMPARATOR
Intervention: Rusk powder (placebo) for 10 weeks
Number of subjects: 83
Study 29021123 — intervention group
Group type: EXPERIMENTAL
Intervention: RBCs stored longer than 35 days
Number of subjects: 24736
Study 29021123 — intervention group
Group type: COMPARATOR
Intervention: RBCs stored no longer than 7 days
Number of subjects: 24736
Study 29021123 — intervention group
Group type: EXPERIMENTAL
Intervention: RBCs stored 8-35 days
Number of subjects: 24736
Study 25439709 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirror therapy supported by telerehabilitation
Number of subjects: 0
Study 25439709 — intervention group
Group type: COMPARATOR
Intervention: Traditional mirror therapy
Number of subjects: 0
Study 25439709 — intervention group
Group type: COMPARATOR
Intervention: Care as usual
Number of subjects: 0
Study 23823745 — intervention group
Group type: EXPERIMENTAL
Intervention: Homeopathic prophylaxis at drying off
Number of subjects: 24
Study 21565823 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle intervention program delivered by a public health department
Number of subjects: 544
Study 21565823 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes education and risk screening
Number of subjects: 544
Study 21565823 — intervention group
Group type: EXPERIMENTAL
Intervention: Study recruitment process
Number of subjects: 544
Study 19628486 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised exercise intervention (30 min continuous moderate intensity cycle ergometry, twice weekly for 6 weeks)
Number of subjects: 30
Study 19628486 — intervention group
Group type: COMPARATOR
Intervention: Usual care control group
Number of subjects: 30
Study 15356039 — intervention group
Group type: EXPERIMENTAL
Intervention: Etanercept
Number of subjects: 8
Study 15356039 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 12381221 — intervention group
Group type: EXPERIMENTAL
Intervention: Biapenem
Number of subjects: 0
Study 12381221 — intervention group
Group type: COMPARATOR
Intervention: Imipenem/cilastatin
Number of subjects: 0
Study 9646891 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine (administered via dermal patch)
Number of subjects: 6
Study 9646891 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 6
Study 7923540 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetic patients
Number of subjects: 100
Study 7923540 — intervention group
Group type: COMPARATOR
Intervention: Non-diabetic patients
Number of subjects: 100
Study 7923540 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetic patients with degenerative complications
Number of subjects: 100
Study 7923540 — intervention group
Group type: COMPARATOR
Intervention: Non-diabetic patients with degenerative complications
Number of subjects: 100
Study 7923540 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug prescriptions for diabetic patients
Number of subjects: 100
Study 7923540 — intervention group
Group type: COMPARATOR
Intervention: Drug prescriptions for non-diabetic patients
Number of subjects: 100
Study 2800576 — intervention group
Group type: EXPERIMENTAL
Intervention: Butorphanol 2 mg plus diazepam 10 mg
Number of subjects: 100
Study 2800576 — intervention group
Group type: COMPARATOR
Intervention: Thiopental
Number of subjects: 100
Study 2800576 — intervention group
Group type: EXPERIMENTAL
Intervention: Butorphanol/diazepam
Number of subjects: 100
Study 2800576 — intervention group
Group type: COMPARATOR
Intervention: Control group (Thiopental)
Number of subjects: 100
Study 337758 — intervention group
Group type: EXPERIMENTAL
Intervention: Amipaque 290 mg I/ml
Number of subjects: 30
Study 337758 — intervention group
Group type: COMPARATOR
Intervention: Urografin 60% (292 mg I/ml)
Number of subjects: 30
Study 30917673 — intervention group
Group type: EXPERIMENTAL
Intervention: Appearance-framed message
Number of subjects: 104227
Study 30917673 — intervention group
Group type: COMPARATOR
Intervention: Health-framed message
Number of subjects: 104227
Study 27335145 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical rose oil (in the carrier of almond oil)
Number of subjects: 120
Study 27335145 — intervention group
Group type: COMPARATOR
Intervention: Placebo (carrier oil)
Number of subjects: 120
Study 27335145 — intervention group
Group type: COMPARATOR
Intervention: No intervention
Number of subjects: 120
Study 26054452 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment as usual and hypnosis (TAU+HYP)
Number of subjects: 102
Study 26054452 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 102
Study 23241726 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.6 µg·kg·min remifentanil
Number of subjects: 60
Study 23241726 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.9 µg·kg·min remifentanil
Number of subjects: 60
Study 23241726 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.3 µg·kg·min remifentanil
Number of subjects: 60
Study 23241726 — intervention group
Group type: COMPARATOR
Intervention: Saline
Number of subjects: 60
Study 21880278 — intervention group
Group type: EXPERIMENTAL
Intervention: NuvaRing
Number of subjects: 0
Study 21880278 — intervention group
Group type: COMPARATOR
Intervention: Combined oral contraceptive pills (OC)
Number of subjects: 0